Abbott receives Chinese approval for Xience V

Justine Varieur Cadet | | Health Imaging | Diagnostic Imaging
The Chinese State Food and Drug Administration has approved Abbott’s Xience V everolimus-eluting coronary stent system for the treatment of coronary artery disease, the leading cause of death in China.

The Abbott Park, Ill.-based company plans a fourth quarter launch in China. With approval in China, Xience V is now available in every Asia-Pacific market, except Japan.

The clinical program for Xience V includes outstanding long-term results from the SPIRIT family of trials, including data from more than 60 patients based in China.

Justine Varieur Cadet

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.